GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients
Pharmaceutical Technology
JULY 14, 2025
How will RFK Jr’s American dream for vaccines play out? Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. MAXSHOT.PL via Shutterstock.
Let's personalize your content